Featured Articles

  1. Is Cash Pay The Right Model For Your Medicine? 11/13/2024

    A cash pay model for prescription drugs can help biopharmaceutical companies meet consumer expectations. However, the model isn't right for every product; out-of-pocket costs, and a capable pharmacy partner, are two key considerations.

  2. From Bike Mechanic To Surgeon To CEO 11/11/2024

    InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, surgeon, and biopharmaceutical leader.

  3. Mimicking The Hollywood Mindset To Develop Drugs In An Era Driven By Capital Markets 11/7/2024

    Traditional organizational structures often struggle to adapt to the dynamic nature of drug development; consultant Sid Parulkar offers another approach that borrows from the Hollywood film industry.

  4. Partnering To Advance Next Generation Treatments For Breast Cancer 11/5/2024

    Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in treatment and patient outcomes require collaborations that leverage expertise, insights, and capabilities across organizations.

  5. Science Does Not Sell Itself: Designing A Winning Pivotal Trial 11/1/2024

    Pivotal trial design can make or break a new therapy's commercial viability. This article explores how choosing the right patient population, endpoints, and comparator are critical for achieving a favorable outcome and maximizing a therapy's market potential.

  6. A Bioethicist Weighs In On Obesity Drugs 10/31/2024

    Anne Zimmerman, editor-in-chief of the Columbia University online journal, Voices in Bioethics discusses her concerns over the use of GLP-1 weight loss drugs in the U.S.

  7. How Cidara Got Its Molecule Back 10/30/2024

    In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a deal with J&J, is now squarely back in the biotech's hands and moving forward with an aggressive phase 2b study.

  8. Now Is The Time For Philanthropic Venture Capital 10/25/2024

    Longer time horizons and therapeutic area expertise make philanthropy venture capital an attractive option for biopharmaceutical companies developing new products. It can also de-risk funding rounds by helping to bring in additional investors.

  9. AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development 10/23/2024

    Part two of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.

  10. Why Job Rotations Are Critical To Shaping Tomorrow's Leaders 10/22/2024

    Job rotations provide an opportunity for promising, high-potential employees to grow and learn new parts of the business. Kristina Fusella describes the challenges and multifactorial benefits of job rotations as a tool for leadership development at Novo Nordisk.